Low-molecular-weight heparin venous thromboprophylaxis in critically ill patients with renal dysfunction: A subgroup analysis of the PROTECT trial
Open Access
- 1 June 2018
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (6) , e0198285
Abstract
There is concern about excessive bleeding when low-molecular-weight heparins (LMWHs) are used for venous thromboembolism (VTE) prophylaxis in renal dysfunction. Our objective was to evaluate whether LMWH VTE prophylaxis was safe and effective in critically ill patients with renal dysfunction by conducting a subgroup analysis of PROTECT, a randomized blinded trial. We studied intensive care unit (ICU) patients with pre-ICU dialysis-dependent end-stage renal disease (ESRD; pre-specified subgroup; n = 118), or severe renal dysfunction at ICU admission (defined as ESRD or non-dialysis dependent with creatinine clearance [CrCl] post hoc subgroup; n = 590). We compared dalteparin, 5000 IU daily, with unfractionated heparin (UFH), 5000 IU twice daily, and considered outcomes of proximal leg deep vein thrombosis (DVT); pulmonary embolism (PE); any VTE; and major bleeding. Adjusted hazard ratios [HR] were calculated using Cox regression. In patients with ESRD, there was no significant difference in DVT (8.3% vs. 5.2%, p = 0.76), any VTE (10.0% vs. 6.9%; p = 0.39) or major bleeding (5.0% vs. 8.6%; p = 0.32) between UFH and dalteparin. In patients with severe renal dysfunction, there was no significant difference in any VTE (10.0% vs. 6.4%; p = 0.07) or major bleeding (8.9% vs. 11.0%; p = 0.66) but an increase in DVT with dalteparin (7.6% vs. 3.7%; p = 0.04). Interaction p-values for comparisons of HRs (ESRD versus not) were non-significant. In critically ill patients with ESRD, or severe renal dysfunction, there was no significant difference in any VTE or major bleeding between UFH and dalteparin. Patients with severe renal dysfunction who received dalteparin had more proximal DVTs than those on UFH; this finding did not hold in patients with ESRD alone.Keywords
Funding Information
- Canadian Institutes of Health Research (MCT78568)
- Heart and Stroke Foundation of Canada (CA) (T6157, T6950, NA6186)
- Australian and New Zealand College of Anesthetists Research Foundation (07/23)
This publication has 19 references indexed in Scilit:
- Antithrombotic Therapy for VTE DiseaseChest, 2016
- VTE Incidence and Risk Factors in Patients With Severe Sepsis and Septic ShockChest, 2015
- Treatment and Prevention of Heparin-Induced ThrombocytopeniaChest, 2012
- Prevention of VTE in Nonsurgical PatientsChest, 2012
- Dalteparin versus Unfractionated Heparin in Critically Ill PatientsNew England Journal of Medicine, 2011
- CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiencyThrombosis and Haemostasis, 2011
- Disorders of Hemostasis Associated with Chronic Kidney DiseaseSeminars in Thrombosis and Hemostasis, 2010
- Prophylaxis Against Deep Vein Thrombosis in Critically Ill Patients With Severe Renal Insufficiency With the Low-Molecular-Weight Heparin DalteparinAn Assessment of Safety and Pharmacodynamics: The DIRECT StudyArchives of internal medicine (1960), 2008
- Meta-Analysis: Low-Molecular-Weight Heparin and Bleeding in Patients with Severe Renal InsufficiencyAnnals of Internal Medicine, 2006
- 3 Pharmacokinetics of heparin and low molecular weight heparinBailliere's Clinical Haematology, 1990